medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Cataracts in rheumatology

Lascurain L, Barragán-Garfias JA, Ruiz-Cruz M

Language: Spanish
References: 34
Page: 831-839
PDF size: 264.12 Kb.


ABSTRACT

Cataracts are the leading cause of reversible blindness in developing countries, their causes are varied, some are secondary to medications (such as the steroids), or eye diseases like uveitis, which might be associated in some cases with rheumatic conditions. The precise mechanism by which steroids promote cataracts development is not yet known, although it is relevant to be aware of this adverse effect in patients receiving these treatments. The relationship between cataracts and uveitis is important, as it is a common complication in this setting. Surgical management in these cases is more complex compared to those in which concomitant uveitis is not present. The aim of this review is to highlight the relationship and importance of a multidisciplinary approach between ophthalmologists and rheumatologists for providing an adequate management, and achievement of a good visual prognosis.


REFERENCES

  1. Gómez PA, Lansingh VC, Penniecook- Sawyers JA, CelisB, Martínez F, Batlle JF, et al. La catarata sigue siendo laprincipal causa de ceguera en economías emergentes,incluyendo México. Rev Mex Oftalmol 2014; 88 (4): 208-209. DOI:10.1016/j.mexoft.2014.10.001.

  2. Lee CM, Afshari NA. The global state of cataract blindness.Curr Opin Ophthalmol 2017; 28 (1): 98-103. doi: 10.1097/ICU.0000000000000340.

  3. Graue E, Graue E. Oftalmología en la práctica de la medicinageneral [Internet]. 5a ed. Nueva York: McGraw-Hill; 2019.

  4. Thompson J, Lakhani N. Cataracts. Prim Care 2015; 42 (3):409-423. doi: 10.1016/j.pop.2015.05.012.

  5. Liu YC, Wilkins M, Kim T, Malyugin B, Mehta JS. Cataracts.Lancet 2017; 390 (10094): 600-612. doi: 10.1016/S0140-

  6. 6736(17)30544-5.6. Selmi C. Diagnosis and classification of autoimmune uveitis.Autoimmun Rev 2014; 13 (4-5): 591-594. https://doi.org/10.1016/j.autrev.2014.01.006.

  7. Sève P, Kodjikian L, Adélaïde L, Jamilloux Y. Uveitis in adults:what do rheumatologists need to know? Joint Bone Spine2015; 82 (5): 308-314. doi: 10.1016/j.jbspin.2015.06.002.

  8. Carreño MA. Terapia médica actual en reumatología. RevMéd Clín Las Condes 2012; 23 (4): 413-422. DOI: 10.1016/S0716-8640(12)70332-2.

  9. Gupta VB, Rajagopala M, Ravishankar B. Etiopathogenesisof cataract: an appraisal. Indian J Ophthalmol 2014; 62 (2):

  10. 103-110. doi: 10.4103/0301-4738.121141.10. Baheti U, Siddique SS, Foster CS. Cataract surgery in patientswith history of uveitis. Saudi J Ophthalmol 2012; 26(1): 55-60. doi: 10.1016/j.sjopt.2011.10.003.

  11. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ,Louie JS, et al. Guidelines for the use of immunosuppressivedrugs in patients with ocular inflammatory disorders: recommendationsof an expert panel. Am J Ophthalmol 2000;130 (4): 492-513. doi: 10.1016/s0002-9394(00)00659-0.

  12. Jabs DA. Immunosuppression for the uveitides.Ophthalmology 2018; 125 (2): 193-202. doi: 10.1016/j.ophtha.2017.08.007.

  13. Caplan A, Fett N, Rosenbach M, Weth VP, MichelettiRG. Prevention and management of glucocorticoidinducedside effects: a comprehensive review: ocular,cardiovascular, muscular, and psychiatric side effectsand issues unique to pediatric patients. J Am Acad Dermatol2017; 76 (2): 201-207. https://doi.org/10.1016/j.jaad.2016.02.1241.

  14. Black RL, Oglesby RB, Von Sallmann L, Bunim JJ. Posteriorsubcapsular cataracts induced by corticosteroids in patientswith rheumatoid arthritis. JAMA 1960; 174: 166-171. doi:10.1001/jama.1960.63030020005014.

  15. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders.Drug Saf 2008; 31 (2): 127-141. doi: 10.2165/00002018-200831020-00003.

  16. James ER. The etiology of steroid cataract. J Ocul PharmacolTher 2007; 23 (5): 403-420. doi: 10.1089/jop.2006.0067.

  17. Marefat H, Abolhassani H, Ghareje Daghi M, Azizi G,Aghamohammadi A. Early onset steroid induced posteriorsubcapsular cataract in a patient with common variableimmunodeficiency: case reports and review of literature.Eur Ann Allergy Clin Immunol 2016; 48 (5):197-201.

  18. Bielory B, Bielory L. Over-the-counter migration ofsteroid use: impact on the eye. Curr Opin AllergyClin Immunol 2014;14 (5): 471-476. doi: 10.1097/ACI.0000000000000099.

  19. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA,Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversibledamage in patients with systemic lupus erythematosus.Rheumatology (Oxford) 2014; 53 (8): 1470-1476. doi:10.1093/rheumatology/keu148.

  20. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damagein systemic lupus erythematosus and its association withcorticosteroids. Arthritis Rheum 2000; 43 (8): 1801-1808. doi: 10.1002/1529-0131(200008)43:8<1801::AIDANR16>3.0.CO;2-O.

  21. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization ofUveitis Nomenclature (SUN) Working Group. Standardizationof uveitis nomenclature for reporting clinical data. Resultsof the first international workshop. Am J Ophthalmol2005; 140 (3): 509-516. doi: 10.1016/j.ajo.2005.03.057.

  22. Chan NS, Ti SE, Chee SP. Decision-making and managementof uveitic cataract. Indian J Ophthalmol 2017; 65 (12):1329-1339. doi: 10.4103/ijo.IJO_740_17.

  23. Conway MD, Stern E, Enfield DB, Peyman GA. Managementof cataract in uveitis patients. Curr Opin Ophthalmol 2018;29 (1): 69-74. doi: 10.1097/ICU.0000000000000438.

  24. Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puéchal X .Ocular inflammatory diseases associated with rheumatoidarthritis. Nat Rev Rheumatol 2014; 10 (2): 108-116. doi:10.1038/nrrheum.2013.185.

  25. Jancevski M, Foster CS. Cataracts and uveitis. CurrOpin Ophthalmol 2010; 21 (1): 10-14. doi: 10.1097/ICU.0b013e328332f575.

  26. Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, BrézinAP, Chee SP, et al. Guidance on noncorticosteroid systemicimmunomodulatory therapy in noninfectious uveitis:Fundamentals Of Care for UveitiS (FOCUS) initiative.Ophthalmology 2018; 125 (5): 757-773. doi: 10.1016/j.ophtha.2017.11.017.

  27. Guindolet D, Dureau P, Terrada C, Edelson C, Barjol A, CaputoG, et al. Cataract surgery with primary lens implantation inchildren with chronic uveitis. Ocul Immunol Inflamm 2018;26 (2): 298-304. doi: 10.1080/09273948.2016.1213855.

  28. Chen JL, Bhat P, Lobo-Chan AM. Perioperative managementof uveitis cataracts. Adv Ophthalmol Optom 2019; 4: 325-339. doi: 10.1016/j.yaoo.2019.04.014.

  29. Meier FM, Tuft SJ, Pavésio CE. Cataract surgery in uveitis.Ophthalmol Clin North Am 2002; 15 (3): 365-373. doi:10.1016/s0896-1549(02)00033-0.

  30. Llop SM, Papaliodis GN. Cataract surgery complications inuveitis patients: a review article. Semin Ophthalmol 2018;33 (1): 64-69. doi: 10.1080/08820538.2017.1353815.

  31. García de Oteyza G, Gómez A, de la Paz M. Corneal meltingafter cataract surgery in a patient with autoimmunedisease. Arch Soc Esp Oftalmol 2017; 92 (11): 535-538. doi:10.1016/j.oftal.2017.06.010.

  32. Ryu SJ, Kang MH, Seong M, Cho H, Shin YU. Anterior scleritisfollowing intravitreal injections in a patient with rheumatoidarthritis: a case report. Medicine (Baltimore) 2017;96 (47): e8925. doi: 10.1097/MD.0000000000008925.

  33. Smolin G, Foster CS, Azar DT, Dohlman CH. Smolin andThoft’s the cornea: scientific foundations and clinicalpractice. 4ª ed. EUA: Lippincott Williams & Wilkins,2005; 564.

  34. Concha del Río LE, Garza MA, González E, Recillas C, VoorduinS, Ruiz-Cruz M, et al. Guías mexicanas para el manejode uveítis no infecciosa en adultos. [Internet]. México:Centro Mexicano de Enfermedades Inflamatorias Oculares(CMEIO), AC; 2019. [consultado 2020 abril 28]. Disponibleen: https://www.smo.org.mx/archivos/documentos/Guias%20Manejo%20Uveitis%20No%20Infecciosa%20en%20Adultos%20CMEIO%202019.pdf.




2020     |     www.medigraphic.com